{"id":"W4379795143","doi":"10.1136/annrheumdis-2023-eular.1533","title":"AB1098 DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Biotech; Manchester Biomedical Research Centre; Sanofi Genzyme; LEO Pharma; Astellas Pharma; Eisai; University of Glasgow; Genentech; University of Oxford; National Institute for Health and Care Research; Glenmark Pharmaceuticals; UCB Pharma; Valeant Pharmaceuticals International; Argenx; Pfizer; Icahn School of Medicine at Mount Sinai; Biogen; University of Rochester; Incyte; Prothena; Sun Pharma; Dermira; Regeneron Pharmaceuticals; Galderma; University of Manchester; XBiotech; Brigham and Women's Hospital; Kyowa Hakko Kirin; Sanofi; Celgene; GlaxoSmithKline; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Johns Hopkins University; Amgen","keywords":"Medicine; Plaque psoriasis; Psoriasis; Dermatology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001270391,0.0005974264,0.001166134,0.0002676423,0.0004135135,0.000922595,0.0003695947,0.000667575,0.001685627],"category_scores_gemma":[0.0006067025,0.0001806818,0.001061082,0.000248452,0.0003198765,0.0007038899,0.0002566061,0.002015988,0.0005906724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007219015,"about_ca_system_score_gemma":0.000758742,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001259362,"about_ca_topic_score_gemma":0.002451808,"domain_scores_codex":[0.9994993,0.0001516035,0.00002311328,0.00006459667,0.0001013428,0.0001599849],"domain_scores_gemma":[0.9994656,0.00008976966,0.00009763761,0.00005330635,0.00007935051,0.000214405],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1702704,0.06029988,0.0474828,0.0007189276,0.002232881,0.0006978193,0.0002756912,0.004137979,0.05756633,0.0004004519,0.01735921,0.6385577],"study_design_scores_gemma":[0.08625313,0.4907329,0.3679167,0.0002137962,0.002154626,0.002332467,0.000408316,0.005188402,0.01831457,0.0009709558,0.02539174,0.0001223539],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888875,0.00475875,0.0004373163,0.0008167779,0.00009899479,0.0004889272,0.001124217,0.0001223157,0.003265134],"genre_scores_gemma":[0.9910095,0.002494771,0.0006269688,0.001059977,0.00008958574,0.0003070312,0.002575435,0.0000297294,0.001807158],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001685627,"threshold_uncertainty_score":0.006718516,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04608898550564392,"score_gpt":0.3176447665533801,"score_spread":0.2715557810477362,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}